Right Where Care Begins
PolyPid is an innovative biopharmaceutical company dedicated to improving patient outcomes by developing long-acting, controlled-release medicines that deliver therapy precisely at the site of care, improving outcomes across surgical care, metabolic diseases, and beyond.
About UsRedefining the Surgical Standard
Our lead product, D-PLEX100, incorporates the proprietary Kynatrix™ technology and represents a first-in-class incisional prophylactic therapy for the prevention of surgical site infections (SSIs). It introduces long-awaited advancement in SSI prevention by enabling localized, prolonged antibiotic exposure directly at the surgical incision.
By delivering concentrated, broad-spectrum antibiotics at the incision site for 30 days, the most critical postoperative risk period. D-PLEX100 has demonstrated a clinically meaningful 60% reduction in surgical site infections compared with standard of care.
Constant and Consistent Drug Release
The Kynatrix™ technology enables customizable, localized, extended drug delivery over periods ranging from days to weeks, without burst effects, ensuring linear, high-concentration exposure across a broad range of therapeutic agents.
Our technology
Novel, Proprietary Technology
Validated, Clinically Proven
Unmatched Application Versatility
Robust Innovative Pipeline
Contact Us
